Direct marking is where UDI compliance stops being a label exercise and becomes a device-lifecycle traceability problem
Reusable surgical instruments and other devices can be separated from their packaging, reprocessed, and used repeatedly over many years. When the label is gone, the device still needs to be identifiable. That is why FDA and EU expectations around direct marking matter: the UDI must remain available at the point of use, reprocessing, investigation, and recall.
This white paper explains the direct marking requirement for medical device manufacturers selling in the U.S. and Europe, including how to determine whether a device is in scope, what implementation options exist, and how to document exceptions without creating inspection risk.
What’s inside
- Determine direct marking applicability: assess whether reusable, reprocessed, or label-separated devices require a permanent UDI on the device itself.
- Compare U.S. and EU expectations: understand where FDA UDI rules and EU MDR/IVDR requirements align, diverge, and create implementation questions.
- Select marking technologies: evaluate laser etching, dot peen, chemical etching, labels, and other approaches against device material, size, safety, and readability needs.
- Document exceptions: prepare rationale for cases where direct marking is not feasible, would compromise safety or effectiveness, or is otherwise exempt.
- Build inspection-ready evidence: connect labeling decisions, device master data, reprocessing instructions, and UDI records into a defensible process.
Why direct marking matters
The foundation of the UDI system is simple: identify the device throughout distribution and use. Direct marking extends that principle to devices that outlive their original packaging. For reusable instruments, implants, endoscopes, orthopedic tools, and similar products, the UDI can support traceability across cleaning, sterilization, use, service, and post-market investigation.
The compliance challenge is not only whether a mark can be applied. Manufacturers also have to decide which devices are subject to the requirement, whether the label already sits on the device, how the mark affects safety or performance, and how the approach fits the global product identification strategy. Those decisions only hold up under inspection when they are backed by reliable device master data and disciplined data integrity practices linking each mark to its UDI record.
KPIs to manage UDI direct marking readiness
Strong programs measure readiness across scope, execution, data, and exception management. These are program metrics to track; they are not invented performance claims.
What the white paper covers
- Direct marking requirements: when the UDI must appear directly on the device, not only on packaging or labeling.
- Devices subject to direct marking: reusable and reprocessed devices, non-sterile orthopedic implants, and other device categories that require careful review.
- Implementation approach: how to evaluate label location, device use, reprocessing instructions, product family scope, and regional deadlines.
- Marking technologies: practical considerations for permanence, readability, device material, cleaning/sterilization, and manufacturing feasibility.
- Exceptions and rationale: when direct marking may not be required or may be impractical, and how to document the decision.
Who should download it
- Regulatory Affairs leaders responsible for UDI strategy, FDA compliance, EU MDR/IVDR readiness, and global product identification.
- Quality, labeling, and data governance teams managing inspection-ready UDI records and change control.
- Manufacturing, operations, and engineering teams selecting marking methods and validating durability/readability.
- Medical device executives who need a defensible plan for portfolio-level UDI direct marking compliance.
When reprocessing, marking, or distribution is handled by parties other than the original manufacturer, the rationale and records behind each device determination need the same rigor — a discipline that overlaps with third-party risk management across your supplier and service network.
FAQ: UDI direct marking in the U.S. and Europe
What is direct marking for a medical device?
Direct marking is the application of the UDI permanently on the device itself, rather than only on its packaging or label. It matters most for devices that can be separated from their packaging and reused — reusable instruments, implants, endoscopes, orthopedic tools, and similar products — so the device stays identifiable at the point of use, reprocessing, investigation, and recall.
How do I know whether a device is subject to direct marking?
Determining applicability means reviewing whether the device is reusable or reprocessed, whether the label is separated from the device in use, whether it is an implant or other category requiring careful review, and how regional UDI rules apply. The white paper walks through how to assess label location, device use, reprocessing instructions, and product family scope to reach a defensible in-scope or out-of-scope decision.
How do U.S. and EU direct marking expectations differ?
Both the FDA UDI framework and the EU MDR/IVDR apply the same underlying principle — identify the device throughout distribution and use — but they differ in scope, applicability, and implementation detail. The white paper highlights where the requirements align, where they diverge, and where those differences create practical implementation questions for manufacturers selling in both markets.
What marking technologies are available, and how do I choose one?
Options include laser etching, dot peen, chemical etching, and labels, among others. The right choice depends on permanence, readability, device material and size, the effect of cleaning and sterilization, manufacturing feasibility, and any impact on the device’s safety or performance. The paper covers the practical considerations for evaluating each approach against your device families.
What happens when direct marking is not feasible?
Direct marking may not be required or may be impractical in certain cases — for example, when it would compromise the device’s safety or effectiveness. In those situations you need documented rationale: the regulatory basis, the technical justification, a risk assessment, and an approval trail. The white paper explains how to capture exceptions so they hold up under inspection rather than becoming a finding.
Download the white paper
Get the full guidance on UDI direct marking applicability, U.S. and EU expectations, marking technologies, and exception documentation. Download The Direct Marking of Medical Devices in the U.S. and Europe using the form on this page, or contact USDM to talk through your portfolio-level UDI direct marking plan.